Khloris Biosciences, Inc.
5729 Fontanoso Way
About Khloris Biosciences, Inc.
Pioneering Cancer Vaccination Defining the Future of Cancer and Cardiovascular Medicine
Khloris is the first and only company to develop an iPSC-derived whole cell vaccine for the treatment of cancer. Fundamentally differentiated from previous cancer vaccinations, iPSC vaccination combines key mechanistic elements to boost anti-tumor immunity. Presenting a broad spectrum of oncofetal and other cancer-related antigens, iPSC vaccination fully mobilizes the immune system.
Khloris is also developing iPSC-derived cardiomyocytes as a novel cell therapy treatment for patients with cardiovascular diseases.
1 article with Khloris Biosciences, Inc.
Leaps by Bayer and Khloris join forces to develop induced pluripotent stem cells (iPSCs) as breakthrough anti-cancer vaccines
Leaps by Bayer, the investment arm of the global life sciences company Bayer, and Khloris Biosciences, a biotechnology company, announced today that they have joined forces to develop novel, first-in-class anti-cancer vaccines based on human induced pluripotent stem cells (iPSCs).